<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03554616</url>
  </required_header>
  <id_info>
    <org_study_id>ITDCZN11</org_study_id>
    <nct_id>NCT03554616</nct_id>
  </id_info>
  <brief_title>Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets</brief_title>
  <official_title>Efficacy of Three Different Bi-treated Long Lasting Insecticidal Nets and Deployment Strategy for Control of Malaria Transmitted by Pyrethroid Resistant Vectors: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kilimanjaro Christian Medical Centre, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The massive scale-up of Long Lasting Insecticidal Nets (LLIN) has led to a major reduction in
      malaria burden (up to 50%) in many sub-Saharan African countries. This progress is threatened
      by the wide scale selection of insecticide resistant malaria vectors. New types of LLIN
      combining a mixture of two insecticides or an insecticide and a synergist have been developed
      to control resistant mosquitoes.

      The efficacy of three bi-treated LLIN are compared to a standard LLIN in a four-arm, single
      blinded, cluster-randomized trial in Misungwi district, Tanzania. The arms are; 1/ Royal
      Guard, a net combining pyriproxyfen (PPF), which is known to disrupt female reproduction and
      fertility of eggs, and the pyrethroid alpha-cypermethrin, 2/Interceptor G2, LLIN
      incorporating a mixture of two adulticides with different modes of action; chlorfenapyr and a
      pyrethroid (alpha-cypermethrin), and 3/ Olyset Plus an LLIN which incorporates a synergist,
      piperonyl butoxide (PBO), to enhance the potency of pyrethroid insecticides, and 4/ The
      control arm: Interceptor treated a standard LLIN treated with alpha-cypermethrin.

      The primary outcome of the trial will be cross-sectional community prevalence of malaria
      infection (by RDT) in children aged 6 months to 14 years at 12 and 24 months
      post-intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malaria infection prevalence in children 6 months to 14 years</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)/plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malaria infection prevalence in children 6 months to 14 years</measure>
    <time_frame>24 months post intervention</time_frame>
    <description>Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)/plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of malaria cases in children 6 months to 10 years</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>Malaria incidence cases will be assessed using Malaria Rapid Diagnostic test (CareStart)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anaemia in children under 5 years old</measure>
    <time_frame>12, 18, 24 and 30 months post intervention</time_frame>
    <description>Hemoglobin (Hb) concentration will be tested to assess anaemia (&lt;8 g/dL) using HemoCue Hb 201+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indoor Anopheles density</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>Anopheles density per house per night will be assess every quarter in 8 houses per cluster using light trap. Anopheles density and sporozoite rate will be used to estimate the entomological inoculation rate (EIR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sporozoite rate</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>A sub-samples of Anopheles collected indoor will be tested for Plasmodium falciparum circumsporozoite protein using an ELISA test. Sporozoite rate will be used to estimate the EIR with Anopheles density.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insecticide content in Long Lasting Insecticidal Net (LLIN)</measure>
    <time_frame>at 0, 12, 24 and 30 months post intervention</time_frame>
    <description>30 LLINs will be collected at yearly interval and Insecticide content in g/kg assessed with High-performance liquid chromatography (HPLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in Anopheles after one hour exposure to every study LLIN</measure>
    <time_frame>at 0, 6, 12, 18, 24 and 30 months post intervention</time_frame>
    <description>30 LLINs will be sampled every 6 months and tested in cone bio assay or tunnel test using resistant Anopheles and susceptible Kisumu Anopheles to assess for bio efficacy. 24, 48 and 72 hours mortality post exposure will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LLIN usage</measure>
    <time_frame>at 6, 12, 18, 24, 30 months post intervention</time_frame>
    <description>The proportion of study participant declaring sleeping under a LLIN the previous night will be assessed during household survey every 6 months using a questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria infection prevalence in children 6 months to 14 years</measure>
    <time_frame>30 months post intervention</time_frame>
    <description>Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)/plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria infection prevalence in children 6 months to 14 years</measure>
    <time_frame>18 months post intervention</time_frame>
    <description>Malaria prevalence will be assessed using Malaria Rapid Diagnostic test (CareStart Malaria histidine-rich protein 2 (HRP2)/plasmodium lactate dehydrogenase (pLDH) Combo, DiaSys, UK)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insecticide resistance intensity in wild Anopheles population</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>Twice a year insecticide resistance will be assessed in wild Anopheles. 24 hours mortality will be recorded in Anopheles exposed to different concentrations of insecticides in CDC bottle assay or WHO test</description>
  </other_outcome>
  <other_outcome>
    <measure>P450 over-expression in wild Anopheles population</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>P450 genes involved in pyrethroid insecticide resistance will be monitored in the 4 arms once a year using reverse-transcription quantitative polymerase chain reaction (PCR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Vgsc mutation in wild Anopheles population</measure>
    <time_frame>Two years post intervention follow up</time_frame>
    <description>A sub sample of mosquitoes collected in the 4 arms will be tested for the Vgsc mutation involved in pyrethroid resistance using Taq Man PCR.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost of each type of bi-treated LLIN</measure>
    <time_frame>Two years post intervention</time_frame>
    <description>Cost of each intervention will be gathered and used to calculate cost per malaria case averted and cost per DALY averted</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4200</enrollment>
  <condition>Malaria</condition>
  <condition>Anaemia</condition>
  <arm_group>
    <arm_group_label>Pyriproxyfen LLIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorfenapyr LLIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperonyl butoxide LLIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard LLIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chlorfenapyr LLIN</intervention_name>
    <description>Dual active ingredient Long Lasting Insecticidal Net</description>
    <arm_group_label>Chlorfenapyr LLIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pyriproxyfen LLIN</intervention_name>
    <description>Dual active ingredient Long Lasting Insecticidal Net</description>
    <arm_group_label>Pyriproxyfen LLIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Piperonyl butoxide LLIN</intervention_name>
    <description>Combination insecticide and synergist Long Lasting Insecticidal Net</description>
    <arm_group_label>Piperonyl butoxide LLIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard LLIN</intervention_name>
    <description>Standard Long Lasting Insecticidal Net with one insecticide</description>
    <arm_group_label>Standard LLIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one child between 6 months to 14 years old having permanent residence in
             selected household

          -  Having an adult caregiver willing to provide written consent for the household and
             clinical survey

        Exclusion Criteria:

          -  Dwelling not found or vacant during the survey

          -  No adult caregiver capable to give informed consent

          -  Children severely ill
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natacha Protopopoff, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank W Mosha, Phd</last_name>
    <phone>+255626316317</phone>
    <email>fwmosha@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alphaxard Manjurano, Phd</last_name>
    <phone>+255756026661</phone>
    <email>amanjurano@yahoo.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>District Misungwi</name>
      <address>
        <city>Misungwi</city>
        <state>Mwanza</state>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Mosha, MD, Phd</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <link>
    <url>http://www.who.int/malaria/areas/vector_control/use-of-pbo-treated-llins-report-nov2015.pdf</url>
    <description>WHO, Conditions for deployment of mosquito nets treated with a pyrethroid and piperonyl butoxide, G.M. Programme, Editor. 2017, World Health Organization: Geneva.</description>
  </link>
  <reference>
    <citation>Asidi A, N'Guessan R, Akogbeto M, Curtis C, Rowland M. Loss of household protection from use of insecticide-treated nets against pyrethroid-resistant mosquitoes, benin. Emerg Infect Dis. 2012 Jul;18(7):1101-6. doi: 10.3201/eid1807.120218.</citation>
    <PMID>22709930</PMID>
  </reference>
  <reference>
    <citation>Ochomo EO, Bayoh NM, Walker ED, Abongo BO, Ombok MO, Ouma C, Githeko AK, Vulule J, Yan G, Gimnig JE. The efficacy of long-lasting nets with declining physical integrity may be compromised in areas with high levels of pyrethroid resistance. Malar J. 2013 Oct 24;12:368. doi: 10.1186/1475-2875-12-368.</citation>
    <PMID>24156715</PMID>
  </reference>
  <reference>
    <citation>Protopopoff N, Mosha JF, Lukole E, Charlwood JD, Wright A, Mwalimu CD, Manjurano A, Mosha FW, Kisinza W, Kleinschmidt I, Rowland M. Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial. Lancet. 2018 Apr 21;391(10130):1577-1588. doi: 10.1016/S0140-6736(18)30427-6. Epub 2018 Apr 11.</citation>
    <PMID>29655496</PMID>
  </reference>
  <reference>
    <citation>N'Guessan R, Odjo A, Ngufor C, Malone D, Rowland M. A Chlorfenapyr Mixture Net Interceptor® G2 Shows High Efficacy and Wash Durability against Resistant Mosquitoes in West Africa. PLoS One. 2016 Nov 16;11(11):e0165925. doi: 10.1371/journal.pone.0165925. eCollection 2016.</citation>
    <PMID>27851828</PMID>
  </reference>
  <reference>
    <citation>Ngufor C, N'Guessan R, Fagbohoun J, Todjinou D, Odjo A, Malone D, Ismail H, Akogbeto M, Rowland M. Efficacy of the Olyset Duo net against insecticide-resistant mosquito vectors of malaria. Sci Transl Med. 2016 Sep 14;8(356):356ra121. doi: 10.1126/scitranslmed.aad3270.</citation>
    <PMID>27629488</PMID>
  </reference>
  <results_reference>
    <citation>Ranson H, N'guessan R, Lines J, Moiroux N, Nkuni Z, Corbel V. Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol. 2011 Feb;27(2):91-8. doi: 10.1016/j.pt.2010.08.004. Epub 2010 Sep 16. Review.</citation>
    <PMID>20843745</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>February 27, 2019</last_update_submitted>
  <last_update_submitted_qc>February 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malaria</keyword>
  <keyword>Vector Control</keyword>
  <keyword>Long lasting Insecticidal Net</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in each publication will be shared and accessible in the LSHTM repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>The study protocol will be published</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

